Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Anhui Anke Biotechnology (Group) Co's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was ¥0.68.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Anhui Anke Biotechnology (Group) Co's Days Inventory for the
three
months ended in Mar. 2026 was 181.83.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Anhui Anke Biotechnology (Group) Co's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.50.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Anhui Anke Biotechnology (Group) Co's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.49.
Anhui Anke Biotechnology (Group) Co (SZSE:300009) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Anhui Anke Biotechnology (Group) Co's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Anhui Anke Biotechnology (Group) Co's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Anhui Anke Biotechnology (Group) Co Total Inventories Related Terms
Anhui Anke Biotechnology (Group) Co Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anhui Anke Biotechnology (Group) Co Total Inventories Chart
Anhui Anke Biotechnology (Group) Co Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Anhui Anke Biotechnology (Group) Co (SZSE:300009) has a Total Inventories of ¥274 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Anhui Anke Biotechnology (Group) Co and its competitors.
Is Anhui Anke Biotechnology (Group) Co's Total Inventories too high?
Anhui Anke Biotechnology (Group) Co's current Total Inventories is ¥274 Mil. Overall, Anhui Anke Biotechnology (Group) Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anhui Anke Biotechnology (Group) Co's Total Inventories compare to VRTX and REGN?
Anhui Anke Biotechnology (Group) Co's Total Inventories of ¥274 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Anhui Anke Biotechnology (Group) Co and its competitors. Anhui Anke Biotechnology (Group) Co's current Total Inventories is ¥274 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anhui Anke Biotechnology (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Anhui Anke Biotechnology (Group) Co (SZSE:300009) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.73, compared to a current price of ¥8.68 — trading 19.1% below its estimated fair value. The current Total Inventories is ¥274 Mil. Anhui Anke Biotechnology (Group) Co's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Anhui Anke Biotechnology (Group) Co (SZSE:300009), the current Total Inventories is ¥274 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anhui Anke Biotechnology (Group) Co (SZSE:300009) Overvalued in 2026?
Based on GuruFocus' analysis, Anhui Anke Biotechnology (Group) Co stock appears to be undervalued.
The current stock price of ¥8.68 is trading 19.1% below its estimated GF Value™ of ¥10.73.
GuruFocus considers Anhui Anke Biotechnology (Group) Co to be Modestly Undervalued.
Key valuation signals for SZSE:300009:
Total Inventories: ¥274 Mil
GF Value™: ¥10.73 vs. price of ¥8.68 (19.1% below fair value)
No single metric tells the full story. See the SZSE:300009 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anhui Anke Biotechnology (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceuticals and health-care products. The Company distributes its product in both domestic and overseas markets. The company operates in more than 30 provinces in China.
90GF Score
Get the complete analysis for SZSE:300009
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300009 has been successfully added to your 
